Orchard Therapeutics plc (ORTX) |
|
5.06 0.13 (2.64%)
|
06-06 14:25 |
|
Open: |
4.96 |
Pre. Close: |
4.93 |
|
High:
|
5.1 |
Low:
|
4.95 |
|
Volume:
|
18,813 |
Market Cap:
|
93(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:20:03 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 6.34 One year: 6.93 |
| Support: |
Support1: 4.59 Support2: 3.82 |
| Resistance: |
Resistance1: 5.42 Resistance2: 5.94 |
| Pivot: |
5.16 |
| Moving Average: |
MA(5): 4.95 MA(20): 5.24
MA(100): 5.26 MA(250): 5.16 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 19.9 %D(3): 18.2 |
| RSI: |
RSI(14): 47.8 |
| 52-week: |
High: 7.19 Low: 3.59 |
| Average Vol(K): |
3-Month: 64 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ORTX ] has closed above bottom band by 35.5%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.11 - 5.13 |
5.13 - 5.16 |
|
Low:
|
4.83 - 4.87 |
4.87 - 4.89 |
|
Close:
|
4.88 - 4.94 |
4.94 - 4.98 |
|
Company Description |
|
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. |
Headline News |
Fri, 26 May 2023
Do Traders Think Orchard Therapeutics PLC - ADR (ORTX) Can Turn Around Friday? - InvestorsObserver
Fri, 19 May 2023
Orchard Therapeutics Announces Positive Clinical and Preclinical ... - Marketscreener.com
Sun, 14 May 2023
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension - Yahoo Finance
Tue, 09 May 2023
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price - Simply Wall St
Mon, 24 Apr 2023
Orchard Therapeutics: MLD Opportunity Could Be Larger Than ... - Seeking Alpha
Mon, 13 Mar 2023
Orchard Therapeutics plc (NASDAQ:ORTX) Q4 2022 Earnings Call Transcript - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
18 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
5.4 (%) |
|
% Held by Institutions
|
34.6 (%) |
|
Shares Short
|
81 (K) |
|
Shares Short P.Month
|
109 (K) |
Stock Financials |
|
EPS
|
-10.03 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.51 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-634.1 |
|
Return on Assets (ttm)
|
-28.7 |
|
Return on Equity (ttm)
|
-89.3 |
|
Qtrly Rev. Growth
|
-77.6 |
|
Gross Profit (p.s.)
|
-4.16 |
|
Sales Per Share
|
0.99 |
|
EBITDA (p.s.)
|
-6.18 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-86 (M) |
|
Levered Free Cash Flow
|
-45 (M) |
Stock Valuations |
|
PE Ratio
|
-0.51 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.9 |
|
Price to Sales
|
5.03 |
|
Price to Cash Flow
|
-1.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
